UNSPSC 51262703: Tolazoline hydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C10H12N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E669Z6S1JG, chemically known as 4,5-dihydro-2-(phenylmethyl)-1h-imidazole monohydrochloride but more generally known as tolazoline hydrochloride, which bears US NIH Compound Identifier 6048. European Medicines Agency schedules Tolazoline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04906MIG.

Most nations, for tariff and trade purposes, schedule tolazoline hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, TOLAZOLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tolazoline hydrochloride bears US NLM identifiers UMLS ID C0770500 and NCI Concept Code C66609. SMILES: C1CCC(CC1)CC2=NCCN2.CL.

UNSPSC 51262703 Tolazoline hydrochloride, a Commodity code, shows minimal recent procurement activity aligned with its nominal scope. The recent opportunities tagged under this code—a Seminole County, Florida IFB for naloxone and drug deactivation systems, and a Texas Health and Human Services Commission RFI on direct-to-manufacturer prescription programs—do not reflect purchases of tolazoline hydrochloride specifically. State and local health and human services agencies are the issuing bodies appearing in the record, but the actual commodities being procured (naloxone, drug deactivation equipment, and prescription fulfillment models) diverge substantially from the code's stated product. The mismatch suggests either tagging error or that tolazoline hydrochloride procurement occurs so infrequently in state and local markets that recent opportunities do not reflect the code's intended scope.

The two opportunities present do not establish geographic concentration or a pattern of repeat solicitation under this code. Seminole County's July 2026 IFB sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023 (the date appears inconsistent with the June 2026 posting date in the source). Texas HHS's April 2026 RFI on direct-to-manufacturer prescriptions sought vendor capabilities for implementing a therapeutic pharmacy initiative but did not name specific pharmaceutical products. Neither opportunity reflects active procurement of tolazoline hydrochloride. Business development professionals should treat this code as inactive for near-term pursuit unless additional state or local solicitations for tolazoline hydrochloride emerge.